Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

• Status: Active, not recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy.

In a sub-group of patients coronary flow reserve will be evaluated.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suleyman Demirel University
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Patients with Acute ST Elevation Myocardial Infarction undergoing Primary Percutaneous Coronary intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy (Mehran Score ≥5)

Exclusion Criteria:

• Patients >18 years old with moderate to high risk for contrast induced nephropathy undergoing percutaneous coronary intervention

• Low risk for contrast induced nephropathy (Mehran Score <5)

• Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...)

• Infection

• Pregnancy, Lactation

• Renal failure requiring dialysis

• Hepatic failure

• Allergy to NAC

• History of Asthma

• Chronic nitrate usage

• Malignancy

• Use of corticosteroids

• Leucocytosis,Thrombocytosis,Anemia

• Blood pressure of >180/100mmHg despite anti-hypertensive therapy